Avivagen Inc.
VIV.V
Toronto Stock Exchange Ventures0.01
CAD
+0.01
- -
Avivagen Inc.
VIV.V
(Toronto Stock Exchange Ventures)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Avivagen Inc. was a life sciences firm that focused on the research and development of products to support immune function in animals. Incorporated in 2005 and headquartered in Ottawa, Canada, the company specialized in its proprietary OxC-beta™ technology, which aimed to serve as a non-antibiotic method to enhance health and growth in livestock. Its primary offering, OxC-beta™ Livestock, was developed as an alternative to traditional antibiotics in animal feeds, having undergone numerous trials in poultry and swine. The company also historically developed health supplements for companion animals, such as Vivamune™ health chews, and explored applications for human immune system support. Avivagen pursued commercialization and regulatory approvals in various international markets, including the United States, Canada, the Philippines, Taiwan, Thailand, China, Mexico, Brazil, Australia, Vietnam, and Malaysia. However, after years of financial losses and facing ongoing challenges, Avivagen Inc. filed for bankruptcy and ceased operations in April 2024.